After that excursion to plant Novazyme, we go back to the development of a treatment for Pompe disease.
The results of the clinical trials, corporate shenanigans and subsequent buy-out of Synpac had left patients feeling uneasy. The Rotterdam (and Duke) results had been promising yet the corporate turbulence had confused the picture. What exactly was going on? Could we still rely on genzyme? What was going to happen next?
At the AGSD-UK conference, held in Oxford in September 2000, we got some answers.
An attached IPA meeting ensured a good international presence and genzyme sent over a high-powered delegation, including Jan van Heek, second in command of the company. That itself sent a message that they meant business.
What follows in the next couple of posts is the account that originally appeared on GSDNet at the time, complete with some contemporary photographs.